Dihydrotachysterol Therapy for Hypoparathyroidism: Consequences of Inadequate Monitoring. Five Cases and a Review

 

 Buy Article Permissions and Reprints

Abstract

Background: The half synthetic Vitamin D analogue dihydrotachysterol (DHT) is widely used for hypocalcaemic hypoparathyroidism following surgical removal of parathyroids. Such treatment generally initiated by surgeons right after surgery has to be continued in clinical practice. Unfortunately, the required careful monitoring of calcium metabolism is often lacking and as demonstrated may lead to life-threatening conditions. Patients and Methods: Here we report on five patients referred to our nephrology unit because of unknown impairment of renal function during therapy with DHT. All patients had clinical signs of hypercalcaemia. Since most symptoms are nonspecific they were not perceived by primary care physicians. In fact DHT treatment was continued for 4 - 50 years. In all cases calcium levels were determined after inadequate long intervals ranging from 3.08 to 4.97 mmol/l. Creatinine levels ranged from 277 to 365 µmol/l. All patients suffered from symptoms of severe hypercalcaemia, three of them needing intensive care unit treatment. Results: All patients were treated effectively with a regimen consisting of intravenous saline, a loop diuretic, and application of bisphosphonates. As confirmed by renal biopsy persisting alleviation of renal function was due to calcifications. After discontinuation of DHT therapy patients were safely switched to shorter acting vitamin D derivates maintaining a normal calcium level. Conclusions: In comparison to short acting vitamin-D derivates hypercalcaemic episodes with DHT appear to last longer and may therefore occur with higher incidence. A future option could be the use of synthetic parathyroid hormone (s-PTH) recently shown to be safe and effective. Nevertheless a customized therapy and careful monitoring is indispensable in any case to prevent irreversible organ damage.

References

• 1 Blind E, Fassnacht M, Korber C, Korber-Hafner N, Reiners C, Allolio B. Severe vitamin D(dihydrotachysterol)-intoxication with temporary anemia and hypercalcemia responsive to bisphosphonates.  Dtsch Med Wochenschr. 2001;  126 T21-T24
  Article in Thieme ConnectPubMedGoogle Scholar
• 2 Bushinsky D A, Monk R D. Electrolyte quintet: Calcium.  Lancet. 1998;  352 306-311
  CrossrefPubMedGoogle Scholar
• 3 Jehle D R, Keller F, Schwarz A, Jehle P M. Hypercalcemia-induced renal insufficiency during therapy with dihydrotachysterol.  J Med. 1999;  30 39-50
  PubMedGoogle Scholar
• 4 Lamberg B A, Tikkanen M J. Hypercalcaemia due to dihydrotachysterol treatment in patients with hypothyroidism after thyroidectomy.  Br Med J (Clin Res Ed). 1981;  283 461-462
  PubMedGoogle Scholar
• 5 Lee K W, Cohen K L, Walters J B, Federman D G. Iatrogenic vitamin D intoxication: report of a case and review of vitamin D physiology.  Conn Med. 1999;  63 399-403
  PubMedGoogle Scholar
• 6 Mason R S, Lissner D, Grunstein H S, Posen S. A simplified assay for dihydroxylated vitamin D metabolites in human serum: application to hyper- and hypovitaminosis D.  Clin Chem. 1980;  26 444-450
  PubMedGoogle Scholar
• 7 McIntyre C W, Schroeder N J, Burrin J M, Cunningham J. Effects of new analogues of vitamin D on bone cells: implications for treatment of uremic bone disease.  Kidney Int. 1999;  55 500-511
  CrossrefPubMedGoogle Scholar
• 8 Pattou F, Combemale F, Fabre S, Carnaille B, Decoulx M, Wemeau J L, Racadot A, Proye C. Hypocalcemia following thyroid surgery: incidence and prediction of outcome.  World J Surg. 1998;  22 718-724
  CrossrefPubMedGoogle Scholar
• 9 Pettifor J M, Bikle D D, Cavaleros M, Zachen D, Kamdar M C, Ross F P. Serum levels of free 1,25-dihydroxyvitamin D in vitamin D toxicity.  Ann Intern Med. 1995;  122 511-513
  PubMedGoogle Scholar
• 10 Puig J, Corcoy R, Rodriguez-Espinosa J. Anemia secondary to vitamin D intoxication.  Ann Intern Med. 1998;  128 602-603
  PubMedGoogle Scholar
• 11 Schilling T, Ziegler R. Current therapy of hypoparathyroidism - a survey of German endocrinology centers.  Exp Clin Endocrinol Diabetes. 1997;  105 237-241
  PubMedGoogle Scholar
• 12 Slatopolsky E, Finch J, Brown A. New vitamin D analogs.  Kidney Int. 2003;  85 (Suppl) 83-87
  PubMedGoogle Scholar
• 13 Steddon S J, Schroeder N J, Cunningham J. Vitamin D analogues: how do they differ and what is their clinical role?.  Nephrol Dial Transplant. 2001;  16 1965-1967
  PubMedGoogle Scholar
• 14 Suda T, Hallick R B, DeLuca H F, Schnoes H K. 25-hydroxydihydrotachysterol. Synthesis and biological activity.  Biochemistry. 1970;  9 1651-1657
  CrossrefPubMedGoogle Scholar
• 15 Vieth R. Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety.  Am J Clin Nutr. 1999;  69 842-856
  CrossrefPubMedGoogle Scholar
• 16 Winer K K, Yanovski J A, Cutler Jr G B. Synthetic human parathyroid hormone 1-34 vs calcitriol and calcium in the treatment of hypoparathyroidism.  Jama. 1996;  276 631-636
  CrossrefPubMedGoogle Scholar
• 17 Winer K K, Ko C W, Reynolds J C, Dowdy K, Keil M, Peterson D, Gerber L H, McGarvey C, Cutler Jr G B. Long-term treatment of hypoparathyroidism: a randomized controlled study comparing parathyroid hormone-(1-34) versus calcitriol and calcium.  J Clin Endocrinol Metab. 2003;  88 4214-4220
  CrossrefPubMedGoogle Scholar

M.D. Lars Christian Rump

Renal Divison
Marienhospital
Ruhr University Bochum

Hoelkeskampring 40

44625 Herne

Phone: + 4923234991670

Fax: + 49 23 23 49 93 02

Email: christian.rump@rub.de